GLP1 Agonists Reduce Major Adverse Liver Outcomes in Chronic Liver Disease

MONDAY, Jan. 29, 2024 -- For patients with chronic liver disease and type 2 diabetes, glucagon-like peptide-1 receptor (GLP1) agonists may result in a lower risk for major adverse liver outcomes (MALO), according to a study published online Jan. 22...
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news